Frost & Sullivan recognises Radisens with 2012 Technology Innovation Award
London – Nov 29, 2012 – Based on its recent analysis of the integrated point-of-care (POC) diagnostic platforms market, Frost & Sullivan recognises Radisens Diagnostics Limited with the 2012 European Technology Innovation Award. Realising the onward surge to integrate POC instruments covering multiple blood test categories, Radisens is developing a single connected multi-diagnostic device, based on its proprietary technology, for long-term chronic disease management. (View the full analyst report here).
“Radisens’ miniaturised POC device and consumable platform integrates different combinations of multiplexed high-sensitivity immunoassays, clinical chemistries, and haematology (cell counting) assays onto single consumable panels,” explained Frost & Sullivan Healthcare Industry Analyst Prasanna Vadhana Kannan. “These panels initially target long-term chronic disease management of thyroid disorders, chronic diabetes, cardiovascular disease, chronic kidney disease, and cell counting.”
This single device thereby effectively replaces the ten to fifteen stand-alone instruments that a physician would typically require for routine blood testing. Moreover, the interpretation of lab-grade data is instantaneous. All sample preparation and blood testing procedures are integrated into the test panel, thereby enabling accurate, highly sensitive, repeatable, sample-to-answer and quality assured results.
“Radisens’ technology platform is truly considered disruptive,” added Kannan. “It seamlessly converges consumer electronics, centrifugal microfluidics, and assay development to achieve smart decentralisation of medical diagnostics from a central reference laboratory into POC settings.”
This platform requires only a finger prick of blood and can deliver clinical results within minutes of blood draw. Through this approach, patients are more likely to improve prescription compliance and, in turn, significantly contribute toward a reduction in the risk factors for chronic disorders. This will impart healthcare systems globally with a much needed tool to combat rising chronic disease management costs.
Notable features that distinguish Radisens’ solution from other competing POC devices in the market include: all assay and sample preparation steps integrated onto a consumable panel, central reference laboratory performance, solid-state digital detection, analyte microanalysis algorithms, and, a single integrated device platform capable of multiplexed diagnostics across the three primary blood test categories of immunoassays, clinical chemistries and cell counting.
“Overall, the potential for Radisens’ diagnostic platform based on its real-time connectivity, sample-to-answer operation, high-degree of multiplexing, and low cost features is immense and is poised to revolutionise the integrated POC diagnostics market,” concluded Kannan.
Frost & Sullivan presents this award to the company that has demonstrated excellence in terms of the uniqueness of its technology and its potential impact on new products/applications, on functionality and on customer value. The company is also commended for the relevance of this innovation to industry.
Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Radisens Diagnostics
Radisens’ mission – to help shape decisions in healthcare by developing a point of care monitoring platform for integrated care management; testing at the right place, at the right time to enable better informed clinical interventions.
Radisens’ focus is to improve the management of high cost chronic diseases. Our early focus is on diabetes and cardiovascular disease, and their associated complexities and complications.
Our vision is to empower both those living with these conditions and their healthcare providers to reduce the challenges and costs of managing these conditions.
Radisens Diagnostics Limited is an established in vitro diagnostics company and was incorporated in 2009 based in Cork, Ireland.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants.
Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructureis entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Radisens Diagnostics Ltd
E: info (at) radisens.com
T: +353 21 4868190 / Fax: +353 21 4928909
Best Practices, Frost & Sullivan
T: +44 (0)20 7915 7869